QS Investors LLC cut its position in Zoetis Inc. (NYSE:ZTS) by 0.3% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 15,291 shares of the company’s stock after selling 52 shares during the period. QS Investors LLC’s holdings in Zoetis were worth $2,850,000 as of its most recent SEC filing.
Other institutional investors have also recently modified their holdings of the company. Dai Ichi Life Insurance Company Ltd raised its holdings in shares of Zoetis by 23.7% during the second quarter. Dai Ichi Life Insurance Company Ltd now owns 114,101 shares of the company’s stock valued at $21,264,000 after purchasing an additional 21,878 shares during the last quarter. LPL Financial LLC boosted its position in shares of Zoetis by 11.3% in the second quarter. LPL Financial LLC now owns 150,366 shares of the company’s stock worth $28,022,000 after purchasing an additional 15,311 shares during the period. Franklin Resources Inc. boosted its position in shares of Zoetis by 3.5% in the second quarter. Franklin Resources Inc. now owns 690,464 shares of the company’s stock worth $128,676,000 after purchasing an additional 23,035 shares during the period. Eudaimonia Partners LLC boosted its position in shares of Zoetis by 96.4% during the second quarter. Eudaimonia Partners LLC now owns 1,469 shares of the company’s stock worth $274,000 after acquiring an additional 721 shares during the last quarter. Finally, Wills Financial Group Inc. boosted its position in shares of Zoetis by 0.5% during the second quarter. Wills Financial Group Inc. now owns 25,050 shares of the company’s stock worth $4,668,000 after acquiring an additional 125 shares during the last quarter. 89.53% of the stock is owned by institutional investors and hedge funds.
A number of equities analysts recently weighed in on ZTS shares. Argus upped their target price on shares of Zoetis from $195.00 to $225.00 and gave the stock a “buy” rating in a research report on Wednesday, August 25th. Barclays upped their price target on shares of Zoetis from $208.00 to $235.00 and gave the company an “overweight” rating in a research note on Friday, August 6th. Raymond James downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating in a research note on Friday, July 16th. Credit Suisse Group upped their price target on shares of Zoetis from $206.00 to $230.00 and gave the company an “outperform” rating in a research note on Monday, August 9th. Finally, Cantor Fitzgerald upped their price target on shares of Zoetis from $210.00 to $238.00 and gave the company an “overweight” rating in a research note on Tuesday, July 13th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $199.82.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, August 5th. The company reported $1.19 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.11. The company had revenue of $1.95 billion for the quarter, compared to the consensus estimate of $1.83 billion. Zoetis had a net margin of 25.76% and a return on equity of 53.87%. During the same quarter last year, the firm posted $0.89 EPS. Analysts predict that Zoetis Inc. will post 4.53 earnings per share for the current fiscal year.
In other Zoetis news, EVP Roman Trawicki sold 4,497 shares of the stock in a transaction dated Friday, October 1st. The shares were sold at an average price of $194.14, for a total transaction of $873,047.58. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Roxanne Lagano sold 22,450 shares of the firm’s stock in a transaction dated Thursday, July 22nd. The shares were sold at an average price of $199.18, for a total transaction of $4,471,591.00. The disclosure for this sale can be found here. Insiders sold a total of 53,815 shares of company stock worth $10,850,755 in the last ninety days. 0.17% of the stock is currently owned by insiders.
Zoetis Company Profile
Zoetis, Inc discovers, develops, and manufactures a portfolio of animal health medicines and vaccines. The firm operates through the following segments: United States &International. Its products are complemented by diagnostic products, genetic tests, bio devices, and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal.
See Also: How to Trade Using Analysts Ratings
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.